Comparison · NCT01792635-2178994d
PF-05175157 200 mg Twice a Day - Part B vs Placebo - Part B: Number of Participants With Laboratory Test Abnormalities in Part B
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PF-05175157 200 mg Twice a Day - Part B vs Placebo - Part B: Number of Participants With Laboratory Test Abnormalities in Part B. Trial comparisons, record NCT01792635-2178994d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01792635-2178994d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.646 | 1 | wilson | |
| Risk in group 2 | 1 | 0.61 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.354 | 0.39 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 1 | 1 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PF-05175157 200 mg Twice a Day - Part B | Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks. | 7 | 7 | OG001 |
| Group 2 | Placebo - Part B | Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks. | 6 | 6 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Laboratory Test Abnormalities in Part B
- Description
Number of participants with laboratory test abnormalities without regard to baseline abnormality. The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell \[RBC\] count, platelet count, white blood cell \[WBC\] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen \[BUN\], creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatine phosphokinase); urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy); others (follicle stimulating hormone \[FSH\], urine drug screen, lipid profile and very-low-density lipoproteins \[VLDL\], hemoglobin A1c \[HbA1c\], C-peptide, thyroid-stimulating hormone \[TSH\], Hepatitis B and C, human immunodeficiency virus \[HIV\], triglycerides, urine creatinine).
- Time frame
- Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration)
- Population
- All participants who were admitted to the Clinical Research Unit (CRU) on Day -5
Source ClinicalTrials.gov
Trial
- Title
- A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
- NCT number
- NCT01792635
- Phases
- PHASE2
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-05175157, Placebo
- Lead sponsor
- Pfizer
- Results first posted
- 2017-02-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01792635?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01792635-2178994d